Kyverna Therapeutics (KYTX) Operating Expenses (2023 - 2026)

Kyverna Therapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at $41.4 million for Q1 2026.

• Quarterly Operating Expenses fell 12.74% year-over-year to $41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.8 million (up 1.95% YoY) and the FY2025 annual result came in at $169.8 million, up 19.09% from the prior year.
• Operating Expenses was $41.4 million for Q1 2026 at Kyverna Therapeutics, up from $39.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $47.4 million in Q1 2025 and bottomed at $11.4 million in Q1 2023.
• A 4-year average of $32.0 million and a median of $38.7 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses soared 156.51% — and 2026, when it retreated 12.74%.
• Kyverna Therapeutics' Operating Expenses stood at $21.4 million in 2023, then soared by 91.99% to $41.0 million in 2024, then retreated by 4.29% to $39.3 million in 2025, then grew by 5.31% to $41.4 million in 2026.
• Business Quant data shows KYTX's Operating Expenses at $41.4 million in Q1 2026, $39.3 million in Q4 2025, and $38.7 million in Q3 2025.